Compare Stocks: TELA, PDEX, PROF, and STIM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PDEX Pro-Dex	$65.36 -5.3%	$65.57	$23.47 ▼ $77.00	$209.35M	0.06	52,081 shs	42,756 shs
PROF Profound Medical	$5.85 +0.9%	$6.72	$4.80 ▼ $8.95	$213.88M	0.72	150,139 shs	156,426 shs
STIM Neuronetics	$2.22 -5.1%	$2.69	$0.80 ▼ $3.44	$169.16M	1.16	2.13 million shs	1.30 million shs
TELA TELA Bio	$1.25 +8.7%	$0.89	$0.50 ▼ $1.60	$56.43M	1.36	188,215 shs	336,262 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PDEX Pro-Dex	-1.46%	-4.09%	+11.11%	+12.51%	+103.84%
PROF Profound Medical	+1.40%	+1.05%	-14.71%	-14.83%	+18.61%
STIM Neuronetics	-0.85%	-18.75%	-17.61%	+65.96%	-14.29%
TELA TELA Bio	-7.26%	-11.54%	+55.83%	+59.41%	-22.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PDEX Pro-Dex	$65.36 -5.3%	$65.57	$23.47 ▼ $77.00	$209.35M	0.06	52,081 shs	42,756 shs
PROF Profound Medical	$5.85 +0.9%	$6.72	$4.80 ▼ $8.95	$213.88M	0.72	150,139 shs	156,426 shs
STIM Neuronetics	$2.22 -5.1%	$2.69	$0.80 ▼ $3.44	$169.16M	1.16	2.13 million shs	1.30 million shs
TELA TELA Bio	$1.25 +8.7%	$0.89	$0.50 ▼ $1.60	$56.43M	1.36	188,215 shs	336,262 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PDEX Pro-Dex	-1.46%	-4.09%	+11.11%	+12.51%	+103.84%
PROF Profound Medical	+1.40%	+1.05%	-14.71%	-14.83%	+18.61%
STIM Neuronetics	-0.85%	-18.75%	-17.61%	+65.96%	-14.29%
TELA TELA Bio	-7.26%	-11.54%	+55.83%	+59.41%	-22.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PDEX Pro-Dex	3.00	Buy	$74.00	13.22% Upside
PROF Profound Medical	2.67	Moderate Buy	$11.50	96.58% Upside
STIM Neuronetics	2.60	Moderate Buy	$4.67	110.21% Upside
TELA TELA Bio	2.50	Moderate Buy	$2.14	71.43% Upside

Current Analyst Ratings Breakdown

Latest TELA, PDEX, PROF, and STIM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	TELA TELA Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$2.00
9/25/2026	TELA TELA Bio	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$2.00
9/22/2026	TELA TELA Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/21/2026	PDEX Pro-Dex	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
9/17/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00
9/15/2026	PDEX Pro-Dex	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/14/2026	STIM Neuronetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/11/2026	STIM Neuronetics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/11/2026	PDEX Pro-Dex	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$70.00 ➝ $74.00
9/11/2026	STIM Neuronetics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
9/9/2026	STIM Neuronetics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$6.00

(Data available from 10/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PDEX Pro-Dex	$77.55M	2.70	$3.64 per share	17.94	$14.92 per share	4.38
PROF Profound Medical	$16.10M	13.28	N/A	N/A	$1.83 per share	3.20
STIM Neuronetics	$149.16M	1.13	N/A	N/A	$0.38 per share	5.84
TELA TELA Bio	$80.28M	0.70	N/A	N/A	$0.16 per share	7.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PDEX Pro-Dex	$13.66M	$4.13	15.83	19.45	N/A	17.62%	25.13%	16.02%	10/29/2026 (Estimated)
PROF Profound Medical	-$42.57M	-$0.98	N/A	N/A	N/A	-171.57%	-63.03%	-51.24%	11/12/2026 (Estimated)
STIM Neuronetics	-$39M	-$0.44	N/A	N/A	N/A	-19.62%	-125.11%	-22.15%	11/3/2026 (Estimated)
TELA TELA Bio	-$38.83M	-$0.77	N/A	N/A	N/A	-51.53%	-1,320.81%	-59.39%	11/12/2026 (Estimated)

Latest TELA, PDEX, PROF, and STIM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/29/2026	Q1 2027	PDEX Pro-Dex	$0.67	N/A	N/A	N/A	$20.40 million	N/A
9/3/2026	Q4 2026	PDEX Pro-Dex	$0.67	$0.87	+$0.20	$0.87	$19.20 million	$20.41 million
8/11/2026	Q2 2026	STIM Neuronetics	-$0.1230	-$0.05	+$0.0730	-$0.05	$40.17 million	$41.57 million
8/10/2026	Q2 2026	TELA TELA Bio	-$0.1738	-$0.20	-$0.0262	-$0.20	$20.01 million	$19.29 million
8/6/2026	Q2 2026	PROF Profound Medical	-$0.22	-$0.26	-$0.04	$0.26	$4.75 million	$2.48 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PDEX Pro-Dex	N/A	N/A	N/A	N/A	N/A
PROF Profound Medical	N/A	N/A	N/A	N/A	N/A
STIM Neuronetics	N/A	N/A	N/A	N/A	N/A
TELA TELA Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PDEX Pro-Dex	0.28	4.10	2.45
PROF Profound Medical	N/A	6.46	5.31
STIM Neuronetics	2.84	1.88	1.69
TELA TELA Bio	8.82	2.99	2.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PDEX Pro-Dex	15.28%
PROF Profound Medical	47.86%
STIM Neuronetics	53.59%
TELA TELA Bio	94.35%

Insider Ownership

Company	Insider Ownership
PDEX Pro-Dex	45.90%
PROF Profound Medical	1.52%
STIM Neuronetics	8.40%
TELA TELA Bio	1.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PDEX Pro-Dex	206	3.20 million	1.73 million	Not Optionable
PROF Profound Medical	162	36.56 million	35.98 million	Optionable
STIM Neuronetics	658	76.20 million	69.80 million	Optionable
TELA TELA Bio	218	45.14 million	44.65 million	Optionable

TELA, PDEX, PROF, and STIM Headlines

Recent News About These Companies

TELA Bio, Inc. (NASDAQ:TELA) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 30 at 1:58 AM | americanbankingnews.com

TELA Bio gains short-term relief on loan covenants

September 29 at 4:51 PM | tipranks.com

TELA Bio (NASDAQ:TELA) Stock Picked Up by Analysts at Craig Hallum

September 27, 2026 | americanbankingnews.com

Craig-Hallum initiates coverage of TELA Bio at buy

September 26, 2026 | msn.com

TELA Bio, Inc. (NASDAQ:TELA) Stock Has Average Target Price of $2.17

September 25, 2026 | marketbeat.com

Craig Hallum Initiates Coverage on TELA Bio With Buy Rating, $2 Price Target

September 25, 2026 | marketscreener.comM

TELA Bio (NASDAQ:TELA) Now Covered by Craig Hallum

September 25, 2026 | marketbeat.com

Joseph Capper Purchases 25,000 Shares of TELA Bio (NASDAQ:TELA) Stock

September 20, 2026 | americanbankingnews.com

TELA Bio (NASDAQ:TELA) Director Joseph Capper Purchases 25,000 Shares

September 19, 2026 | insidertrades.com

TELA Bio (NASDAQ:TELA) Director Joseph Capper Purchases 25,000 Shares of Stock

September 18, 2026 | marketbeat.com

TELA Bio Faces Nasdaq Delisting, Plans Reverse Split

September 18, 2026 | tipranks.com

TELA Bio (NASDAQ:TELA) Director Buys 25,000 Shares of Stock

September 17, 2026 | insidertrades.com

TELA Bio (NASDAQ:TELA) Director Acquires $25,500.00 in Stock

September 16, 2026 | marketbeat.com

Joseph Capper Purchases 50,000 Shares of TELA Bio (NASDAQ:TELA) Stock

September 16, 2026 | marketbeat.com

TELA Bio chief operating officer and chief financial officer resigns

September 2, 2026 | pennbizreport.comP

Tela Bio cuts 41 jobs in Malvern as new CEO launches $17M cost-reduction plan

September 2, 2026 | msn.com

Malvern medical-tech company is slashing jobs as part of cost-cutting campaign

September 1, 2026 | msn.com

Malvern firm cutting 20% of workforce as new CEO launches cost cuts

August 31, 2026 | bizjournals.com

TELA Bio Announces COO / CFO Transition and Strategic Cost Reduction Initiative

August 31, 2026 | globenewswire.com

TELA Bio (TELA) Q2 2026 Earnings Call Transcript

August 19, 2026 | finance.yahoo.com

Heather Getz Acquires 15,000 Shares of TELA Bio (NASDAQ:TELA) Stock

August 18, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

TELA, PDEX, PROF, and STIM Company Descriptions

Pro-Dex NASDAQ:PDEX

$65.36 -3.64 (-5.28%)

Closing price 04:00 PM Eastern

Extended Trading

$65.54 +0.18 (+0.28%)

As of 04:15 PM Eastern

Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California.

Profound Medical NASDAQ:PROF

$5.85 +0.05 (+0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$5.84 -0.01 (-0.26%)

As of 04:27 PM Eastern

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

Neuronetics NASDAQ:STIM

$2.22 -0.12 (-5.13%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 +0.04 (+1.98%)

As of 07:12 PM Eastern

Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.

TELA Bio NASDAQ:TELA

$1.25 +0.10 (+8.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.26 +0.01 (+0.72%)

As of 05:21 PM Eastern

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELA, PDEX, PROF, and STIM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELA, PDEX, PROF, and STIM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELA, PDEX, PROF, and STIM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TELA, PDEX, PROF, and STIM Company Descriptions

Pro-Dex NASDAQ:PDEX

Profound Medical NASDAQ:PROF

Neuronetics NASDAQ:STIM

TELA Bio NASDAQ:TELA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TELA, PDEX, PROF, and STIM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TELA, PDEX, PROF, and STIM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TELA, PDEX, PROF, and STIM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

TELA, PDEX, PROF, and STIM Company Descriptions

Pro-Dex NASDAQ:PDEX

Profound Medical NASDAQ:PROF

Neuronetics NASDAQ:STIM

TELA Bio NASDAQ:TELA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools